US/UK/Canada

Share

Contacts

  • General Press Enquiries
    For general press enquiries please contact the AbbVie Corporate Communications team at UKMediaRelations@abbvie.com or call us on 01628 925200
    01628 925200
    https://twitter.com/abbvieuk

    • Quotes

    We are delighted that the MHRA has approved risankizumab for use in adults living with active psoriatic arthritis. As a leader in dermatology, AbbVie is committed to improving the quality of life for those with dermatologic comorbidities. Today’s announcement is an important step forward for patients.
    Belinda Byrne, Medical Director, AbbVie UK
    Psoriatic arthritis is a common co-morbidity in people living with psoriasis, the swelling and pain caused by joint inflammation can severely affect a person’s ability to carry out their normal day-to-day activities. Today’s approval is a meaningful milestone in advancing psoriatic arthritis care as we need more treatment options to manage this debilitating, life-long condition and meet the individual needs of our patients.
    Dr Laura Savage, Consultant Dermatologist at Leeds Teaching Hospitals NHS Trust.
    “AbbVie is incredibly proud to be recognised in the Best Workplaces™ list for the 8th year in a row. Participation in a Great Place to Work survey is extremely valuable to us, enabling our employees to share their views and shape our organisation on key areas of our culture, including development and recognition, employee engagement and wellbeing, and organisational leadership.”
    Henri Louw, HR Director at AbbVie UK
    Pick a time period -

    Scottish Medicines Consortium Accepts Chemotherapy-free Combination Treatment VENCLYXTO[®]▼(Venetoclax) Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia

    · Patients in Scotland with previously untreated chronic lymphocytic leukaemia (CLL) now have access to a chemotherapy-free, 12-month, fixed-duration treatment option.[1] · Scottish Medicines Consortium (SMC) acceptance is based on data from the Phase III CLL14 trial, which showed patients receiving 1 year of treatment with venetoclax plus obinutuzumab had superior progression-free survival compared with those receiving a commonly used chemo-immunotherapy regimen of obinutuzumab and chlorambucil, with patients sustaining that benefit after stopping treatment.[2,3] · CLL is the most

    People with Moderate to Severe Uncontrolled Crohn’s Disease Granted Early Access to New Investigational Treatment in the UK

    · The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a positive scientific opinion under the Early Access to Medicines Scheme (EAMS) for risankizumab for the treatment of appropriate adults and adolescents (16-17 years) with Crohn’s disease (CD)[1] · The EAMS is designed to provide early access to promising innovative medicines for UK patients prior to marketing authorisation, where there is a clear unmet clinical need[2] · Risankizumab is the first medicine for inflammatory bowel disease (IBD) that has been made available through the scheme, reinforcing the

    Scottish Medicines Consortium accepts AbbVie’s RINVOQ[®▼] (upadacitinib) for Use in Adolescents and Adults with Active Atopic Dermatitis (eczema)

    · Scotland the first nation in the UK to provide access via the NHS to upadacitinib for people with moderate to severe eczema over 12 years of age, with inadequate response to at least one conventional systemic immunosuppressant, or to whom such treatment is considered unsuitable[1] · Upadacitinib demonstrated clinically meaningful itch reduction and skin clearance within 2 weeks across four clinical trial programmes[2] · The SMC advice will provide access to the first advanced treatment in pill form for adolescents with AD in Scotland · Upadacitinib is now available across three

    Scottish Medicines Consortium Accepts VENCLYXTO[®]▼(venetoclax) Combination in Patients with the Aggressive Blood Cancer Acute Myeloid Leukaemia

    · For the first time in Scotland, venetoclax in combination with azacitidine will be available to untreated adult patients with Acute Myeloid Leukaemia (AML) unable to receive intensive chemotherapy (IC)[1]  · The venetoclax combination has demonstrated the ability to offer these patients significantly improved overall survival, increased rates of rapid and durable remission and blood transfusion independence, compared with treatment with azacitidine alone[2] · AML is an acute leukaemia that can cause symptoms very quickly, requiring treatment as soon as possible after diagnosis[3]

    NICE recommends AbbVie’s RINVOQ[® ▼ (upadacitinib) ]For Use in Adults with Active Psoriatic Arthritis

    · This decision means that upadacitinib will be available in England and Wales for eligible patients with previously treated active psoriatic arthritis (PsA).[1] · Across pivotal clinical trial programmes, upadacitinib (15 mg, once daily) demonstrated efficacy across multiple measures of disease activity in psoriatic arthritis (PsA) with a safety profile consistent with that seen in rheumatoid arthritis (RA)[2,3,4] · Upadacitinib now MHRA-approved across four indications (atopic dermatitis, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis)MAIDENHEAD, UK, 11[th]

    NICE Recommends VENCLYXTO[®]▼(Venetoclax) Combination in Certain Patients with the Aggressive Blood Cancer Acute Myeloid Leukaemia (AML)

    · Venetoclax in combination with azacitidine will be immediately available to untreated adult patients with AML unable to receive intensive chemotherapy (IC)[1] · The combination has demonstrated ability to offer these patients significantly improved overall survival, increased rates of rapid and durable remission and blood transfusion independence, compared with treatment with azacitidine alone[2] · Clinical experts describe the combination as the greatest advance in 30 years[3] for those unable to receive IC for this aggressive, difficult-to-treat blood cancer, which has a low

    AbbVie’s SKYRIZI[®] ▼ (risankizumab) Receives MHRA Approval For Use In Adults with Active Psoriatic Arthritis

    · Risankizumab is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs) · Approval is supported by data from pivotal Phase 3 studies KEEPsAKE-1 and KEEPsAKE-2,[1,2,3]demonstrating statistical significance for the primary endpoint of ACR20 response for efficacy and multiple secondary endpoints · The safety profile of risankizumab in psoriatic arthritis was generally consistent with its safety profile in plaque psoriasis patients[4]MAIDENHEAD, UK,

    NICE issues positive Final Appraisal Document for AbbVie’s RINVOQ[®]▼(upadacitinib) in moderate active Rheumatoid Arthritis (RA)

    · Positive recommendation means upadacitinib will be available to those with previously treated moderate active RA[1] · NICE recommendation is based on data from pivotal Phase 3 SELECT clinical trial programme, in which upadacitinib demonstrated improved rates of clinical remission* compared to treatment with placebo; methotrexate (MTX) monotherapy; and adalimumab plus MTX in patients with moderate to severe RA[2-6] · An estimated 400,000 people in the UK live with rheumatoid arthritis[7] and for the majority remission is not achieved currently[8]Maidenhead, UK, 7 October 2021 – The

    AbbVie Presents Late-Breaking Data on Risankizumab (SKYRIZI[®])▼ in Psoriatic Arthritis at the 30th European Academy of Dermatology and Venereology (EADV) Congress

    · Analyses include long-term efficacy and safety data from the open-label extension period of KEEPsAKE-1 and KEEPsAKE-2 evaluating risankizumab in psoriatic arthritis[1] · The primary endpoint of ACR20 response at week 24 was maintained through one year (52 weeks)[1] · Continuous treatment with risankizumab improved signs and symptoms of psoriatic arthritis, with efficacy maintained through one year (52 weeks) of treatment[1] · Results were presented at the 30th European Academy of Dermatology and Venereology (EADV) Virtual Congress MAIDENHEAD, UK., 6 October, 2021– AbbVie (NYSE:

    MHRA Approves RINVOQ[®] ▼ (upadacitinib) as First JAK Inhibitor in GB for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis

    · Approval supported by data from one of the largest registrational Phase 3 programmes in atopic dermatitis evaluating upadacitinib monotherapy or with topical corticosteroids[1] · Upadacitinib met all primary and secondary endpoints, demonstrating[ ]rapid and significant improvement in skin clearance and itch reduction compared to placebo at week 16 and earlier time points (p<0.001)[1] · Results at week 16 continued to be maintained through week 52 [2,3] · Upadacitinib now MHRA-approved across four indications (atopic dermatitis, rheumatoid arthritis, psoriatic arthritis and

    JAMA Dermatology Publishes Data Showing Upadacitinib Achieved Superiority vs Dupilumab for Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis

    · Upadacitinib (30 mg, once daily) monotherapy demonstrated significantly greater rates of skin clearance improvement and itch reduction compared to dupilumab (300 mg, every other week) monotherapy at 16 weeks[1] · Early, significant results were seen in upadacitinib-treated patients – including skin clearance improvements (EASI 75) at two weeks and itch reduction at one week – compared to dupilumab[1] · The safety profile of upadacitinib was consistent with previous atopic dermatitis studies, with no new safety risks observed[1-3] MAIDENHEAD, UK., August 4, 2021 – AbbVie (NYSE:

    AbbVie UK Publishes 2020 Transparency Data; Supporting Collaboration of Medical Opinion Towards Advancing Patient Care and the Development of New Medicines

    Maidenhead, UK, 30 June 2021 – Each year AbbVie discloses individual and aggregated transfers of value to healthcare professionals (HCPs) and healthcare organisations (HCOs) to the Association of the British Pharmaceutical Industry (ABPI). We are pleased to confirm that over 73% of healthcare professionals who received sponsorship, fees or ‘in-kind’ support from AbbVie in 2020, opted-in for their individual data to be made public. The collaboration of medical opinion is essential to advance patient care, gain insights into unmet medical needs and progress the development of new

    New SKYRIZI [® ][]▼ (risankizumab) 150 mg Presentation Pre-filled Pen and Pre-filled Syringe Approved by the Medicines and Healthcare Products Regulatory Agency (MHRA)

    · Risankizumab is now administered as one injection per dose, either by pre-filled pen or pre-filled syringe[1] · Approval based on results showing the new formulation of risankizumab 150 mg demonstrated bioequivalence to two injections of risankizumab 75 mg[1] MAIDENHEAD, UK, June 4, 2021 – AbbVie (NYSE: ABBV) today announced the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved a new risankizumab 150 mg presentation, to be administered by one injection per dose via pre-filled pen or pre-filled syringe every 12 weeks following an initiation dose at week 0 and

    New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ[®] ▼ (upadacitinib) in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress

    · Long-term data from the Phase 3 SELECT-COMPARE trial show that continuous treatment with upadacitinib plus methotrexate (MTX) maintained rates of clinical remission and low disease activity through three years in adults with rheumatoid arthritis[1] · In a separate integrated safety analysis of upadacitinib, no new significant safety findings were observed up to 4.5 years in patients with rheumatoid arthritis[2] · Results from both presentations will be shared at the EULAR 2021 Virtual Congress · Upadacitinib is an oral, once-daily, selective and reversible JAK inhibitor approved

    The Lancet Publishes Results from Pivotal Global Phase 3 Programme Evaluating RINVOQ[®] (upadacitinib) ▼ in Atopic Dermatitis

    MAIDENHEAD, UK, May 24, 2021 – AbbVie (NYSE: ABBV) today announced The Lancet published primary analysis results from the pivotal global Phase 3 clinical trials – Measure Up 1, Measure Up 2 and AD Up – evaluating RINVOQ[®] (upadacitinib) ▼ in adults and adolescents with moderate to severe atopic dermatitis who were candidates for systemic treatment. The results were published in two separate manuscripts as part of the May 22,[ ]2021 issue of The Lancet.  The publication of Measure Up 1 and Measure Up 2 shares efficacy and safety results of patients treated with upadacitinib (15 mg or 30

    SMC Accepts AbbVie’s RINVOQ [® ]▼ (upadacitinib) For Use in Adults with Active Psoriatic Arthritis

    · This decision means that upadacitinib will be available in Scotland for eligible patients with previously treated active psoriatic arthritis (PsA) [1] · Across pivotal clinical trial programmes, upadacitinib (15 mg, once daily) demonstrated efficacy across multiple measures of disease activity in psoriatic arthritis (PsA) with a safety profile consistent with that seen in rheumatoid arthritis (RA)[2,3,4] · Upadacitinib is now the first-ever, once-daily oral JAK approved for the treatment of PsA, ankylosing spondyloarthritis, and rheumatoid arthritis MAIDENHEAD, UK, May 10, 2021 –

    AbbVie is recognised as one of the 2021 UK’s Best Workplaces™

    Thursday, 29[th] April 2021 – Employees have spoken! AbbVie, a research-based global biopharmaceutical company, today announces it has achieved a 16[th] ranking on the 2021 UK’s Best Workplaces™list (in the Large category) published by Great Place to Work® UK today.Constantly striving to reach the best outcomes for patients, is just one of the reasons why employees are proud to work for AbbVie. AbbVie have sustained their position as a leading Pharmaceutical company within our category of the Best Workplaces™ list, with 84% of survey participants saying that ‘This is a Great Place to

    AbbVie report calls for much needed improvements to Shared Decision Making in the NHS

    Maidenhead, UK, 24[th] March, 2021 -- AbbVie, a research-based global biopharmaceutical company, has today launched a policy report looking at the role patients (and their families) should have in the decisions made about their medical care and treatment, known as Shared Decision Making (SDM).The report draws on the findings from AbbVie’s roundtable discussions, chaired by Lib Dem Peer Baroness Judith Jolly and with involvement from key patient advocacy groups, national health and professional bodies, and other parliamentarians to understand how COVID-19 has impacted the implementation of

    SMC Issues Positive Decision for Treatment with AbbVie’s RINVOQ[®]▼(upadacitinib) in Severe Active Rheumatoid Arthritis (RA)

    · Positive indication means upadacitinib will be available to those with previously treated severe active RA[1]* · SMC approval is based on data from pivotal Phase 3 SELECT clinical trial programme, in which upadacitinib demonstrated improved rates of clinical remission** compared to treatment with placebo; methotrexate (MTX) monotherapy; and adalimumab (TNF antagonist) plus MTX in patients with severe RA[2-6] · For the majority of people living with RA, remission is not currently achieved.[7] An estimated 44,000 people in the Scotland live with RA[8]The Scottish Medicines Consortium (

    CHMP Recommends the Approvals of RINVOQ™ (Upadacitinib) ▼ for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis

    · Across pivotal clinical trial programmes, RINVOQ (15 mg, once daily) demonstrated efficacy across multiple measures of disease activity in psoriatic arthritis (PsA) and ankylosing spondylitis (AS), with a safety profile consistent with that seen in rheumatoid arthritis (RA)[1-4] · If approved, RINVOQ will be the first oral, selective and reversible JAK inhibitor approved in three rheumatologic conditions in the European Union: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis · The European Commission decisions for both indications are anticipated in early 2021

    SMC Accepts Chemotherapy-free Combination Treatment VENCLYXTO[®] ▼ (venetoclax) Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia

    ·For the first time in Scotland, certain people with untreated chronic lymphocytic leukaemia (CLL) will have access to a chemotherapy-free, 12-month fixed-duration treatment option.[1] · Scottish Medicines Consortium (SMC) acceptance is based on data from the Phase III CLL14 trial, which showed patients treated with 1 year of treatment with venetoclax plus obinutuzumab had superior progression-free survival and sustained that benefit after stopping treatment, compared with those receiving a commonly used chemo-immunotherapy regimen of obinutuzumab and chlorambucil.[2] · CLL is the

    NICE gives green light for chemotherapy-free combination, Venclyxto® ▼(venetoclax) plus obinutuzumab for all front-line patients with chronic lymphocytic leukaemia (CLL)

    ·Positive recommendation for Venclyxto (venetoclax) means that all previously untreated patients with chronic lymphocytic leukaemia (CLL) will, for the first time, have a chemotherapy-free, fixed-duration treatment option[1 ] ·NICE approval is based on data from Phase III CLL14 trial, which showed that patients treated with 1 year of treatment with venetoclax plus obinutuzumab had superior progression-free survival and sustained that benefit after stopping treatment compared with those receiving a commonly used chemoimmunotherapy regimen of obinutuzumab and chlorambucil[2] · CLL

    NICE Issues Positive Final Appraisal Determination for AbbVie’s RINVOQ[®]▼(upadacitinib) in Severe Active Rheumatoid Arthritis (RA)

    · Positive recommendation means upadacitinib will be available to those with previously treated severe active RA[1]* · NICE approval is based on data from pivotal Phase 3 SELECT clinical trial programme, in which upadacitinib demonstrated improved rates of clinical remission** compared to treatment with placebo; methotrexate (MTX) monotherapy; and adalimumab plus MTX in patients with moderate to severe RA[2-6]  · An estimated 400,000 people in the UK live with rheumatoid arthritis[7 ]and for the majority remission is not achieved currently[8]Maidenhead, UK, Nov. 6[th], 2020 – The

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe